AAVrh10.CAG.hCYP46A1 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病1

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003052-16-FR
(EUCTR)
20/07/202208/12/2021Phase I/II Safety and Tolerability Study of striatal administration of BV-101 in adult subjects with Early Manifest Huntington's Disease (HD)An Open-Label Phase I/II Dose Finding Study to evaluate the Safety, Tolerability, and Preliminary Efficacy of Striatal Administration of BV-101 in Adult Subjects with Early Manifest Huntington's Disease (HD) Huntington's disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AAVrh10.CAG.hCYP46A1
Product Code: BV-101
INN or Proposed INN: AAVrh10.CAG.hCYP46A1
Other descriptive name: ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 CONTAINING THE HUMAN CHOLESTEROL 24-HYDROXYLASE GENE
BrainvectisNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
18Phase 1;Phase 2United States;France